Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Recruiting 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Immunoglobulin Light-chain Amyloidosis 3Multiple Myeloma 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Interventional × Focal Adhesion Protein-Tyrosine Kinases × Clear all
NCT05695508 2025-12-24

HD10/DSMMXX

University of Heidelberg Medical Center

Phase 2 Recruiting
160 enrolled
Plasma cell

Multiple Myeloma

NCT07079423 2025-07-23

Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis

Peking Union Medical College Hospital

Phase 2 Recruiting
35 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06935162 2025-05-25

Teclistamab in Previously Treated AL Amyloidosis

Peking Union Medical College Hospital

Phase 2 Recruiting
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06699394 2025-04-24

Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis

Peking University People's Hospital

Phase NA Recruiting
20 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡